955 F.3d 25
Fed. Cir.2020Background
- Valeant owns U.S. Patent No. 8,552,025 claiming a methylnaltrexone injectable solution with pH "between about 3.0 and about 4.0;" claim 8 adds a limitation of stability: storage 24 months at about room temperature (stipulated as ≤2.0% degradants and pharmaceutically suitable).
- Mylan filed an ANDA to market a generic Relistor® product, conceded infringement of claim 8, and defended on obviousness grounds (prior art formulations of naloxone/naltrexone and pharmaceutical treatises).
- Key prior art: Bahal (stable naloxone formulations pH 3.0–3.5), Oshlack (naltrexone formulations pH ~3–5, preferably ~4), Fawcett (naltrexone pH ~3.5); treatises (Gibson, Remington) teach pH-dependent stability and that pH ~3–4 often minimizes hydrolysis.
- District court granted Valeant summary judgment, rejecting Mylan’s obviousness theory because the cited art did not disclose methylnaltrexone formulations, relied on stabilizers, and the court held the claimed pH/stability result was not shown to be predictable or "obvious to try."
- The Federal Circuit reversed and remanded: it held that overlapping pH ranges in prior art for structurally and functionally similar opioid antagonists can establish a prima facie case of obviousness; it also found the district court erred in its obvious-to-try analysis and in resolving factual disputes at summary judgment.
Issues
| Issue | Plaintiff's Argument (Valeant) | Defendant's Argument (Mylan) | Held |
|---|---|---|---|
| Whether claim 8 is obvious based on prior art pH ranges for similar compounds | Overlapping pH ranges for different drugs that do not show the claimed 24‑month stability do not establish obviousness; structural differences matter | Overlapping pH ranges for structurally/functionally similar opioid antagonists (naloxone, naltrexone) create a prima facie case of obviousness for methylnaltrexone | Reversed: overlapping prior-art pH ranges for similar compounds can establish a prima facie case of obviousness and Mylan raised such a case |
| Whether the claimed pH range was "obvious to try" (finite, predictable options) | Prior art did not disclose the claimed long‑term stability; district court correctly found the pH options are not meaningfully finite | pH 3–4 is a bounded, practically discrete domain (given routine measurement precision) and thus an obvious-to-try, predictable solution | Reversed: district court erred; pH 3–4 presents a finite/practical set of options and obvious-to-try may apply |
| Whether factual disputes (e.g., experts, predictability, role of stabilizers) precluded summary judgment | Experts and art show that stabilizers or other variables were needed; no expectation of the claimed 24‑month stability based on pH alone | Expert testimony and prior art support an expectation that similar compounds would behave similarly at similar pH and raise disputed facts | Reversed: district court improperly resolved factual disputes at summary judgment; those issues should be decided after factual development |
Key Cases Cited
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (obvious-to-try/practical-motivation framework)
- In re Peterson, 315 F.3d 1325 (overlapping ranges can create prima facie obviousness)
- Graham v. John Deere Co., 383 U.S. 1 (Graham factual inquiries for obviousness)
- Daiichi Sankyo Co. v. Matrix Labs., Ltd., 619 F.3d 1346 (structural similarity informs obviousness)
- In re Dillon, 919 F.2d 688 (structural similarity supports motivation to modify)
- In re Deuel, 51 F.3d 1552 (structural relationships and motivation analysis)
- In re Merck & Co., Inc., 800 F.2d 1091 (use of prior art compounds with similar pharmacological utility)
- Anacor Pharms., Inc. v. Iancu, 889 F.3d 1372 (expectation of shared properties among similar compounds)
- In re Geisler, 116 F.3d 1465 (critically evaluating claimed ranges and rebuttal evidence)